Evidence map›Paper›PMID 27539090›Full record

ArticleThe British journal of ophthalmology2017

Retinal reattachment and ERG recovery after ophthalmic artery chemosurgery for advanced retinoblastoma in eyes with minimal baseline retinal function.

Aliaa H Abdelhakim, Jasmine H Francis, Brian P Marr, Y Pierre Gobin, David H Abramson, Scott E Brodie

Open access · greenAbstract read
In one paragraph

Article in The British journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Aliaa H AbdelhakimOphthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jasmine H FrancisOphthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Brian P MarrOphthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Y Pierre GobinOphthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
David H AbramsonOphthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Scott E BrodieOphthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

aimTo report retinal function outcomes after ophthalmic artery chemosurgery (OAC) for advanced retinoblastoma (RB) in eyes with minimal pretreatment retinal function.

methodsFor 72 advanced RB eyes with baseline electroretinograms (ERGs) indistinguishable from noise ('extinguished') or flicker ERG amplitudes <25 µV ('poor'), ERGs were obtained before OAC and at 3 months, 1 year and 2 years after OAC. Presence of baseline retinal detachments (RDs) and their subsequent resolution or persistence was also noted.

resultsAt 3 months, 1 year and 2 years post-OAC, 'extinguished' eyes showed 9/15, 4/11 and 2/6 detectable ERGs, respectively, and 'poor' eyes showed 19/55, 14/30 and 8/18 ERGs exceeding 25 μV, respectively. Correlations between baseline and post-OAC ERGs were poor; however, good correlation (R

conclusionsMinimal baseline ERGs do not preclude significant recovery of retinal function after OAC. Good correlation exists between ERG outcomes at 3 months and those at subsequent follow-ups, suggesting that ERG amplitudes at 3-month post-OAC can prognosticate longer term retinal function, and that improvement is durable. For eyes presenting with RD, RD resolution is necessary but not sufficient for significant (≥25 μV) increases in ERG amplitudes.

Indexed as

Antineoplastic AgentsChildDisease-Free SurvivalElectroretinographyFemaleHumansInfusions, Intra-ArterialMaleMelphalanOphthalmic ArteryRetinal DetachmentRetinal NeoplasmsRetinoblastomaRetrospective StudiesSalvage TherapyAntineoplastic AgentsMelphalanElectrophysiologyRetinaTreatment Surgery

Identifiers

PMID27539090
PMCPMC5637273
OpenAlexW2515602081

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.